&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-14, 09:14

Repeat: Thunder Bridge Capital Partners IV, Inc. Announces Effectiveness of Registration Statement and Special Meeting Date for Proposed Business Combination with Coincheck, Inc.
Tamika Gonzalez

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-12, 23:05

The Sanborn Map Company, Inc. Receives Certification to ISO 9001:2015 Standard
Britney MacDevitt

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Monique Kunkel

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Melvina Mahler

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-29, 00:59

Berman Tabacco Announces Investigation of Evolv Technologies Holdings, Inc. (EVLV, EVLVW) Concerning Accounting Practices
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-03, 22:18

Dark Horse Consulting Group Acquires BioTechLogic, Inc.
Tony Loman

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-18, 22:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai
Danny Gaylord

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-18, 22:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai
Edith Snider

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-03, 20:25

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to "Thank God I Got It" by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-22, 03:15

Olaplex Holdings, Inc. Announces Participation in the Barclays 17th Annual Global Consumer Staples Conference on September 4th
Tony Loman

Popular Posts